All About Multiple Sclerosis

More MS news articles for May 2004

Effects of altered peptide ligands (APLs) of proteolipid(136-150) on T-cell clone 4B.14a

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15163393

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003 Jul;19(4):387-9
Geng TC.
Department of Neurology, China-Japan Friendship Hospital, Beijing 100029, China.

AIM:

By investigating the effects of APLs of PLP(136-150) on T cell clone 4B.14a in-vitro and in-vivo, to determine the feasibility of APLs to prevent relapsing multiple sclerosis (MS) in human.

METHODS:

To mimic the clinic course of relapsing MS, SJL/J female mice were first irradiated at 450R and intravenously infused with 1x10(7) resting 4B.14a T cells per mouse.

Then mice were immunized with 50 microg/mouse APL for inducing passive experiment allergic encephalomyelitis (EAE).

The proliferation and cytokine production of 4B.14a T cells in response to APLs were also examined.

RESULTS:

Except 139A, 143A, 144A, 145A and 148A, other APLs triggered T cells to induce passive EAE; 4B.14a T cells well responded to the most APLs, weakly responded to 137A, 144A and 148A, but the response was suppressed by 139A.

CONCLUSION:

The effects of some APLs on 4B.14a T cells are different in-vitro and in-vivo.

It may be feasible to select some APLs to prevent relapsing MS in human.